{"id":11371,"date":"2020-12-08T13:57:23","date_gmt":"2020-12-08T08:27:23","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=11371"},"modified":"2025-05-06T15:19:00","modified_gmt":"2025-05-06T09:49:00","slug":"pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","title":{"rendered":"KaliVir, Astellas licensing deal; AbCellera&#8217;s IPO; Bayer CAR-T Cell therapy collab with Atara;  Aligos, Merck together against NASH"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a08b780befef\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a08b780befef\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\/#KaliVir_Astellas_Pharma_forms_a_licensing_deal_for_VET2-L2_oncolytic_virus\" >KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\/#AbCellera_Biologics_readies_to_raise_up_to_USD_391_million_in_IPO\" >AbCellera Biologics readies to raise up to USD 391 million in IPO<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\/#Bayer_collaborates_with_Atara_Biotherapeutics_for_off-the-shelf_CAR_T-Cell_Therapy\" >Bayer collaborates with Atara Biotherapeutics for off-the-shelf CAR T-Cell Therapy&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\/#Aligos_Therapeutics_Merck_team_up_to_discover_and_develop_an_Oligonucleotide_Therapy_for_NASH\" >Aligos Therapeutics, Merck team up to discover and develop an Oligonucleotide Therapy for NASH<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"KaliVir_Astellas_Pharma_forms_a_licensing_deal_for_VET2-L2_oncolytic_virus\"><\/span><strong>KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.&nbsp;<\/p>\n\n\n\n<p>As its lead program, KaliVir is developing <strong>VET2-L2<\/strong> leveraging its unique technology platform based on a genetically modified vaccinia virus. VET2-L2 is an oncolytic vaccinia virus that can be delivered intravenously to cancer patients. This will reduce the need for complicated procedures of the direct intra-tumoral administration and will be of huge convenience for patients. The therapy is in the preclinical stage.<\/p>\n\n\n\n<p>The deal brings together KaliVir&#8217;s expertise in the development of oncolytic viruses with Astellas&#8217; capabilities in advanced drug development. Under the terms of the agreement, Astellas is going to shell out an upfront sum up to USD 56 million in addition to the payments supporting the ongoing research, development, and pre-clinical activities surrounding VET2-L2 as well as the Second Product. KaliVir may also receive up to US$307 million and up to US$271 million for the development, regulatory, and commercialization of VET2-L2 and Second Product, respectively, and royalty payments on net sales of each licensed product.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AbCellera_Biologics_readies_to_raise_up_to_USD_391_million_in_IPO\"><\/span><strong>AbCellera Biologics readies to raise up to USD 391 million in IPO<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Canadian antibody-drug discovery platform AbCellera Biologics is setting the groundwork for a massive Initial public offering worth USD 391 million.&nbsp;<\/p>\n\n\n\n<p>The company made a mark when it struck a deal with the pharmaceutical engine, Eli Lilly, to work on its <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\" target=\"_blank\" rel=\"noreferrer noopener\">COVID 19 therapy<\/a> &#8211; human antibody <strong>bamlanivimab <\/strong>&#8211; which managed to secure EUA with the USFDA. Not to lose sight of AbCellera\u2019s AI-powered antibody discovery platform that speeds up the process of finding antibodies that can be developed into drugs. Further, the company has the support of PayPal founder and tech\/life sciences investor Peter Thiel, German entrepreneur Christian Angermayer, the Bill &amp; Melinda Gates Foundation, Viking Global Investors, and healthcare investment firm OrbiMed Advisors LLC in addition to a grant of USD 175.6 million from the Canadian government.\u00a0<\/p>\n\n\n\n<p>The company is offering 23 million shares priced between USD 14 and USD 17 each. It is being estimated that this IPO if successful, will be the biggest debut on record for Canadian biotech.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_collaborates_with_Atara_Biotherapeutics_for_off-the-shelf_CAR_T-Cell_Therapy\"><\/span><strong>Bayer collaborates with Atara Biotherapeutics for off-the-shelf CAR T-Cell Therapy&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Germany-based life sciences titan, Bayer, has set out on a collaborating spree to explore CAR-T cell gene therapy and oncology. Not long ago, the acquisition of an N.C.-based gene therapy company <a href=\"https:\/\/www.delveinsight.com\/blog\/latest-pharma-happenings-for-bayer-askbio-novartis-forma-epicgenetics\/\" target=\"_blank\" rel=\"noreferrer noopener\"><strong>AskBio <\/strong>by Bayer<\/a> made headlines. Last year, Bayer had got its hands on another cell and gene therapy company, <strong>BlueRock Therapeutics<\/strong>.\u00a0<\/p>\n\n\n\n<p>And now the next step towards bolstering its strategic presence in the cell &amp; gene therapy market, Bayer has collaborated with Bay Area-based Atara Biotherapeutics.<\/p>\n\n\n\n<p>The doubleton through collaboration will focus on developing off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors. It covers Atara\u2019s two developmental candidates, <strong>ATA3271<\/strong>, an armored allogeneic T-cell immunotherapy, and an autologous version, and <strong>ATA2271<\/strong>, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.<\/p>\n\n\n\n<p>While ATA3271, the allogeneic version of this CAR-T, leverages Atara\u2019s EBV T-cell platform and is currently in IND-enabling studies, ATA2271, the autologous version has enrolled the first patient in an open-label, single-arm Phase 1 clinical study in November 2020.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Aligos_Therapeutics_Merck_team_up_to_discover_and_develop_an_Oligonucleotide_Therapy_for_NASH\"><\/span><strong>Aligos Therapeutics, Merck team up to discover and develop an Oligonucleotide Therapy for NASH<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Aligos Therapeutics has entered into an exclusive license and research collaboration agreement with Merck with a motive to get rid of the hassle due to <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\" target=\"_blank\" rel=\"noreferrer noopener\">non-alcoholic steatohepatitis<\/a> (NASH) by developing oligonucleotide therapies.\u00a0<\/p>\n\n\n\n<p>Under the terms of the deal, the duo plans to leverage Aligos\u2019 oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a NASH target as well as another additional target of interest in the cardiometabolic\/fibrosis space. In exchange for its platform, Aligos will receive an upfront payment as well as additional milestone payments.&nbsp;<\/p>\n\n\n\n<p>Aligos will be committed to designing, preparing, and evaluating the oligonucleotide molecules and delivering optimized lead molecules, Merck, on the other hand, will lead in the research, clinical development, and commercialization efforts.<\/p>\n\n\n\n<p>While the NASH market seems lucrative, the past failures and setbacks faced by the therapies and their pharma owners have nothing but a dejection. After <strong>Gilead<\/strong>, <strong>Intercept<\/strong>,&nbsp; <strong>Genfit<\/strong>, and <strong>Albireo <\/strong>&#8211; all reported disappointing results in their respective NASH programs, the market picture was a bit grim. However, it seems the potential and opportunity the NASH market landscape has up its sleeves outweighs the risks.&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market.&nbsp; As its lead program, KaliVir is developing VET2-L2 leveraging its unique technology [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":11375,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[107,1976,15648,268,395,427],"industry":[17225],"therapeutic_areas":[17245,17228,17234],"class_list":["post-11371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bayer","tag-car-t-cell-therapy","tag-covid-19-vaccines","tag-gilead-biosciences","tag-merck","tag-oncology","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>KaliVir, Astellas deal; AbCellera IPO; Bayer&#039;s CAR-T collabs; NASH market<\/title>\n<meta name=\"description\" content=\"KaliVir, Astellas licensing deal; AbCellera USD 391M IPO; Bayer CAR T-Cell therapy collab with Atara; Aligos, Merck together for NASH therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KaliVir, Astellas deal; AbCellera IPO; Bayer&#039;s CAR-T collabs; NASH market\" \/>\n<meta property=\"og:description\" content=\"KaliVir, Astellas licensing deal; AbCellera USD 391M IPO; Bayer CAR T-Cell therapy collab with Atara; Aligos, Merck together for NASH therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-08T08:27:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T09:49:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH market","description":"KaliVir, Astellas licensing deal; AbCellera USD 391M IPO; Bayer CAR T-Cell therapy collab with Atara; Aligos, Merck together for NASH therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","og_locale":"en_US","og_type":"article","og_title":"KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH market","og_description":"KaliVir, Astellas licensing deal; AbCellera USD 391M IPO; Bayer CAR T-Cell therapy collab with Atara; Aligos, Merck together for NASH therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-12-08T08:27:23+00:00","article_modified_time":"2025-05-06T09:49:00+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News.jpg","type":"image\/jpeg"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera","name":"KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH market","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News.jpg","datePublished":"2020-12-08T08:27:23+00:00","dateModified":"2025-05-06T09:49:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"KaliVir, Astellas licensing deal; AbCellera USD 391M IPO; Bayer CAR T-Cell therapy collab with Atara; Aligos, Merck together for NASH therapy","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-bayer-astellas-merck-aligos-abcellera#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News.jpg","width":772,"height":482,"caption":"KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH therapy"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/12\/08134849\/Pharma-News-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Covid-19 vaccines<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Oncology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/span>","<span class=\"advgb-post-tax-term\">Covid-19 vaccines<\/span>","<span class=\"advgb-post-tax-term\">Gilead Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Dec 8, 2020","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Dec 8, 2020 1:57 pm","modified":"Updated on May 6, 2025 3:19 pm"},"featured_img_caption":"KaliVir, Astellas deal; AbCellera IPO; Bayer's CAR-T collabs; NASH therapy","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=11371"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11371\/revisions"}],"predecessor-version":[{"id":31751,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/11371\/revisions\/31751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/11375"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=11371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=11371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=11371"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=11371"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=11371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}